$125 to $300 is where it should be and I would be happy as well. It will no longer be Anavex after that price and the share structure will change dramatically to pay for rapid growth to support what a big pharma would need (which is basically to pad the wallets of 100 Misslings) abd not their actual staff. If for some odd reason Anavex does not sell to an established big pharma with experience rolling out drugs on a large scale worldwide it will dilute like crazy. Shares will multiply as fast as the current administration prints worthless currency.
News 
Market Data 
Discover 
AI
